These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17265808)

  • 21. Antiplatelet agents in atherothrombotic diseases.
    Rao U; Weston C
    Hosp Med; 2004 Feb; 65(2):72-5. PubMed ID: 14997771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases.
    Bhatt DL; Kapadia SR; Yadav JS; Topol EJ
    Cerebrovasc Dis; 2000; 10 Suppl 5():34-40. PubMed ID: 11096181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
    Granitskiĭ NA
    Kardiologiia; 2006; 46(5):73-5. PubMed ID: 16858363
    [No Abstract]   [Full Text] [Related]  

  • 24. Perioperative use of anti-platelet drugs.
    Chassot PG; Delabays A; Spahn DR
    Best Pract Res Clin Anaesthesiol; 2007 Jun; 21(2):241-56. PubMed ID: 17650775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of antiplatelet therapy for minimization of bleeding risk before cardiac surgery.
    Weant KA; Flynn JF; Akers WS
    Pharmacotherapy; 2006 Nov; 26(11):1616-25. PubMed ID: 17064207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clopidogrel in the prevention of stroke].
    Nagy V; Fehér J
    Orv Hetil; 2004 Dec; 145(51):2563-7. PubMed ID: 15715289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant?
    Curzen N; Sambu N
    Heart; 2011 Sep; 97(17):1433-40. PubMed ID: 21821634
    [No Abstract]   [Full Text] [Related]  

  • 28. Future of oral antiplatelet therapy: four challenged hypotheses.
    Serebruany VL; Makarov LM
    Thromb Haemost; 2009 Jun; 101(6):1041-3. PubMed ID: 19492145
    [No Abstract]   [Full Text] [Related]  

  • 29. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
    Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
    Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of acute coronary syndromes.
    Peverill RE; Moir S
    N Engl J Med; 2002 Jan; 346(3):206-8. PubMed ID: 11797721
    [No Abstract]   [Full Text] [Related]  

  • 31. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation.
    Rinfret S; Rodés-Cabau J; Bagur R; Déry JP; Dorais M; Larose E; Barbeau G; Gleeton O; Nguyen CM; Noël B; Proulx G; Roy L; Taillon I; De Larochellière R; Bertrand OF;
    Heart; 2013 Apr; 99(8):562-9. PubMed ID: 23434769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.
    Schulman SP
    JAMA; 2004 Oct; 292(15):1875-82. PubMed ID: 15494586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A guide to drug use during percutaneous coronary intervention.
    Choo JK; Young JJ; Kereiakes DJ
    Drugs; 2002; 62(18):2589-601. PubMed ID: 12465999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes.
    Alagona P
    J Invasive Cardiol; 2010 Jan; 22(1):40-4. PubMed ID: 20048399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.
    Angiolillo DJ
    Diabetes Care; 2009 Apr; 32(4):531-40. PubMed ID: 19336638
    [No Abstract]   [Full Text] [Related]  

  • 38. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral antiplatelet therapy for percutaneous coronary revascularization.
    Hamdalla H; Steinhubl SR
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):637-42. PubMed ID: 17351930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
    Steinhubl S; Berger P
    Am Heart J; 2003 Jun; 145(6):971-8. PubMed ID: 12796751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.